Insider Selling: PTC Therapeutics (NASDAQ:PTCT) VP Sells 2,813 Shares of Stock

February 20, 2026 by InsiderTrades.com

Key Points

Insider selling: VP Mark Elliott Boulding sold 3,081 shares on Feb. 18 at an average $69.36 (about $213,698) and roughly 5,894 shares across Feb. 17–18, reducing his stake by 2.77% to 108,231 shares.
Q4 miss and lowered outlook: PTC reported a large Q4 shortfall (EPS $(1.67) vs. $(0.21) expected; revenue $164.7M vs. $281.5M expected, down ~22.7% YoY) and set FY-2026 revenue guidance of $700–$800M well below street estimates (~$974M).
Offsetting factors: the company ended 2025 with about $1.95B in cash and noted early uptake of Sephience, while analysts maintain a "Moderate Buy" consensus with an average target of $80.73.

PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) VP Mark Elliott Boulding sold 2,813 shares of the business's stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $69.29, for a total transaction of $194,912.77. Following the transaction, the vice president owned 111,312 shares of the company's stock, valued at approximately $7,712,808.48. This represents a 2.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Mark Elliott Boulding also recently made the following trade(s):

On Wednesday, February 18th, Mark Elliott Boulding sold 3,081 shares of PTC Therapeutics stock. The shares were sold at an average price of $69.36, for a total transaction of $213,698.16.
On Friday, January 9th, Mark Elliott Boulding sold 2,314 shares of PTC Therapeutics stock. The shares were sold at an average price of $77.93, for a total value of $180,330.02.
On Thursday, January 8th, Mark Elliott Boulding sold 4,033 shares of PTC Therapeutics stock. The shares were sold at an average price of $76.56, for a total transaction of $308,766.48.
On Tuesday, January 6th, Mark Elliott Boulding sold 1,739 shares of PTC Therapeutics stock. The stock was sold at an average price of $76.95, for a total transaction of $133,816.05.
On Wednesday, January 7th, Mark Elliott Boulding sold 4,879 shares of PTC Therapeutics stock. The stock was sold at an average price of $77.44, for a total value of $377,829.76.
On Monday, January 5th, Mark Elliott Boulding sold 2,266 shares of PTC Therapeutics stock. The shares were sold at an average price of $75.55, for a total value of $171,196.30.

PTC Therapeutics Stock Performance

Shares of NASDAQ:PTCT traded up $0.12 during trading on Friday, reaching $70.02. The stock had a trading volume of 783,012 shares, compared to its average volume of 1,236,530. PTC Therapeutics, Inc. has a 52 week low of $35.95 and a 52 week high of $87.50. The firm's fifty day moving average is $75.01 and its 200 day moving average is $67.78. The stock has a market cap of $5.62 billion, a price-to-earnings ratio of 8.19 and a beta of 0.48.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last announced its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.67) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($1.46). PTC Therapeutics had a net margin of 42.25% and a negative return on equity of 194.11%. The company had revenue of $164.68 million for the quarter, compared to analyst estimates of $281.45 million. During the same quarter in the prior year, the company posted ($0.85) EPS. PTC Therapeutics's revenue for the quarter was down 22.7% on a year-over-year basis. On average, research analysts forecast that PTC Therapeutics, Inc. will post -4.52 earnings per share for the current fiscal year.

Key PTC Therapeutics News

Here are the key news stories impacting PTC Therapeutics this week:

Positive Sentiment: Full-year product/royalty revenue beat guidance and Sephience™ (sepiapterin) showed strong early uptake (Q4 revenue $92M; 2025 Sephience revenue $111M). Company ended 2025 with $1.95B in cash, supporting runway for commercialization and R&D. PR Newswire
Positive Sentiment: Bank of America cut its price target from $97 to $93 but kept a "buy" rating, implying continued analyst conviction and a material upside from current levels. That endorsement can limit downside and attract buyers. Benzinga
Neutral Sentiment: Earnings-call coverage and analyst note summaries are available that walk through quarter specifics and management commentary — useful for parsing whether revenue mix or one-offs drove the headline miss. Earnings Call Highlights
Negative Sentiment: PTC reported Q4 EPS of ($1.67) vs. consensus ($0.21) and Q4 revenue of $164.7M vs. $281.5M expected — a sizeable miss that directly pressured the stock. Revenue was down ~22.7% year‑over‑year. Zacks: Q4 loss, revenue miss
Negative Sentiment: Management set FY-2026 revenue guidance of $700M–$800M vs. street consensus near $974M — a notable downward gap that reduces near-term upside and raises investor concern about product rollouts/volume. PR Newswire: Guidance
Negative Sentiment: Regulatory headwinds: coverage flagged new questions after PTC withdrew a Translarna NDA, adding uncertainty to that program's prospects and potential future revenue. Yahoo: Translarna questions
Negative Sentiment: Insider selling: VP Mark Boulding sold ~5,894 shares across Feb. 17–18, a small but visible reduction in holdings that can be perceived negatively by some investors. SEC Form 4

Hedge Funds Weigh In On PTC Therapeutics

A number of large investors have recently made changes to their positions in PTCT. Jefferies Financial Group Inc. purchased a new stake in PTC Therapeutics during the 3rd quarter worth about $97,252,000. Janus Henderson Group PLC lifted its holdings in shares of PTC Therapeutics by 28.6% in the fourth quarter. Janus Henderson Group PLC now owns 4,851,332 shares of the biopharmaceutical company's stock worth $368,587,000 after buying an additional 1,077,776 shares in the last quarter. State Street Corp boosted its position in shares of PTC Therapeutics by 34.2% in the fourth quarter. State Street Corp now owns 4,206,126 shares of the biopharmaceutical company's stock valued at $319,497,000 after acquiring an additional 1,071,343 shares during the period. Toronto Dominion Bank grew its stake in PTC Therapeutics by 27.5% during the fourth quarter. Toronto Dominion Bank now owns 4,138,215 shares of the biopharmaceutical company's stock valued at $314,339,000 after acquiring an additional 891,690 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its stake in PTC Therapeutics by 4,013.1% in the 4th quarter. BNP Paribas Financial Markets now owns 828,662 shares of the biopharmaceutical company's stock worth $62,945,000 after purchasing an additional 808,515 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Jefferies Financial Group boosted their price target on shares of PTC Therapeutics from $63.00 to $77.00 and gave the stock a "buy" rating in a report on Tuesday, October 28th. Barclays upgraded PTC Therapeutics from an "equal weight" rating to an "overweight" rating and upped their price objective for the company from $68.00 to $119.00 in a research note on Tuesday, January 27th. Citigroup lifted their target price on PTC Therapeutics from $50.00 to $75.00 and gave the stock a "neutral" rating in a research note on Wednesday, November 5th. Wells Fargo & Company set a $86.00 price target on shares of PTC Therapeutics in a research report on Friday. Finally, Weiss Ratings reaffirmed a "hold (c)" rating on shares of PTC Therapeutics in a research report on Monday, December 29th. Ten research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, PTC Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $80.73.

Get Our Latest Stock Analysis on PTC Therapeutics

About PTC Therapeutics

(Get Free Report)

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company's research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC's approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.